Affiliation:
1. Endocrinology Research Centre
Abstract
Given the increased morbidity and mortality in patients with type 1 diabetes mellitus (T1DM), as well as the burden posed by the disease, the search for methods to prevent the destruction of beta cells is of paramount importance. Until recently, no attempts of immunotherapeutic interventions have achieved significant success, allowing at best reducing the rate of destruction of beta cells without stopping the immune process and not allowing normalization of glycemia. In November 2022, the U.S. Food and Drug Administration (FDA) approved the drug teplizumab to delay clinical diagnosis of T1DM. The purpose of the publication is to evaluate the results of teplizumab treatment in high-risk participants with the second (preclinical) stage of T1DM, as well as to consider further prospects for this treatment.
Publisher
Endocrinology Research Centre
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference15 articles.
1. FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes Accessed November 18, 2022.
2. Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. doi: https://doi.org/10.1056/NEJMoa1902226
3. Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980. doi: https://doi.org/10.1126/scitranslmed.abc8980
4. Waldron-Lynch F, Henegariu O, Deng S, et al. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Sci Transl Med. 2012;4(118). doi: https://doi.org/10.1126/scitranslmed.3003401
5. Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514-518. doi: https://doi.org/10.1038/nature10228